menu
    • menu

    Company profile for Uniqure

    NEW Drugs in Dev: 11
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. We are advancing a focused pipeline of innovative gene therapies. We are currently condu...
    uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. We are advancing a focused pipeline of innovative gene therapies. We are currently conducting a pivotal phase 3 trial in our lead indication, hemophilia B, and have initiated a phase 1/2 trial in Huntington’s disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    UniqureNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Paasheuvelweg 25a 1105BP Amsterdam
    Telephone
    Telephone
    +1 339 970 7000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.uniqure.com/index.php
    Linkedin
    Linkedin
    https://www.linkedin.com/company/uniqure
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/uniQure_NV

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    IMCAS Asia

    IMCAS Asia

    Not Confirmed

    envelop Contact Supplier

    IMCAS Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    UniQure Stock Surges After FDA Clears Path to Gene Therapy
    UniQure Stock Surges After FDA Clears Path to Gene Therapy

    17 Jun 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/uniqure-stock-surges-after-fda-u-turn-clears-path-gene-therapy-filing

    FIERCE BIOTECH
    17 Jun 2026
    Share Share
    UniQure, Replimune Rise After FDA Makary Exit
    UniQure, Replimune Rise After FDA Makary Exit

    13 May 2026

    // BIOSPACE

    https://www.biospace.com/fda/uniqure-replimune-shares-rise-as-fdas-makary-exits-but-path-forward-unchanged

    BIOSPACE
    13 May 2026
    Share Share
    Uniqure Reveals Q1 2026 Financials And Company Updates
    Uniqure Reveals Q1 2026 Financials And Company Updates

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3287519/0/en/uniqure-announces-first-quarter-2026-financial-results-and-provides-recent-company-updates.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Uniqure Advances AMT-130 For Huntington's Disease With UK MHRA
    Uniqure Advances AMT-130 For Huntington's Disease With UK MHRA

    30 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/30/3284703/0/en/uniqure-announces-successful-uk-mhra-pre-submission-meeting-for-amt-130-in-huntington-s-disease.html

    GLOBENEWSWIRE
    30 Apr 2026
    Share Share
    uniQure to Announce First Quarter 2026 Financial Results
    uniQure to Announce First Quarter 2026 Financial Results

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282448/0/en/uniqure-to-announce-first-quarter-2026-financial-results.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Can't Plausible Mechanism Principles Apply To Uniqure
    Can't Plausible Mechanism Principles Apply To Uniqure

    15 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/fda-official-plausible-mechanism-principles-not-exclusive-bespoke-gene-therapies

    FIERCE BIOTECH
    15 Apr 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search